Article Text

Download PDFPDF
Chromatin remodelling controls pancreatic tissue fate
  1. Elisabeth Hessmann,
  2. Volker Ellenrieder
  1. Department Gastroenterology and Gastrointestinal Oncology, University Medical Centre Goettingen, Goettingen, Germany
  1. Correspondence to Professor Volker Ellenrieder, Department Gastroenterology and Gastrointestinal Oncology, University Medical Centre Goettingen, Goettingen 37075, Germany; volker.ellenrieder{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Despite of severe clinical and scientific efforts, treatment of pancreatic ductal adenocarcinoma (PDAC) remains a major challenge. Significant improvement of PDAC prognosis is hampered by restricted therapy response of PDAC patients which is—on the molecular level—primarily caused by an extreme intertumoral heterogeneity.1 Besides the core genetic alterations (oncogenic mutation of KRAS, inactivation of the core tumour suppressors TP53, CDKN2A and DPC4) PDAC is characterised by a plethora of additional molecular events that, although occurring less frequently, are of prognostic and predictive significance.2 3 For instance, approximately one-third of PDAC tumours carry mutations in genes coding for chromatin regulatory proteins.2 Epigenetic alterations installed by changes of the chromatin landscape critically impact on tissue homeoestasis and can foster malignant transformation and tumour progression.1 This is particularly true for the SWI/SNF (SWItch/sucrose non-fermentable) complex of chromatin remodelling proteins, which physiologically disrupts the tight contact between DNA and histones and mobilises nucleosomes to reveal previously …

View Full Text


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Linked Articles